CAMBRIDGE NUTRITIONAL SCIENCES PLC — Director's Dealing 2021

Feb 15, 2021

National Storage Mechanism | Additional information

RNS Number : 0212P

Omega Diagnostics Group PLC

15 February 2021

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Director/PDMR Shareholding

Exercise of Options

and Total Voting Rights

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted in total 1,691,013 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares"). This is following the exercise of share options under the Company's Third Unapproved Scheme by William Rhodes and Jeremy Millard, both Non-Executive Directors, and, under the Company's EMI Option Scheme by Jag Grewal, Commercial Director and Kieron Harbinson, Group Finance Director (together the "Exercising Directors").

In addition to the above dealings by the Exercising Directors, the Company has also received valid notices to exercise a further 74,347 share options from employees under the Company's Sharesave scheme. Of this amount, 5,869 Ordinary Shares were exercised and subsequently sold by Jamie Yexley, Operations Director and PDMR of the Company, at a price of 82.25 pence per Ordinary Share, following this transaction his holding in the Company remains unchanged.

Further to the exercise of share options by the Exercising Directors as detailed above, the Company announces that the Exercising Directors have subsequently sold in aggregate 1,616,666 new Ordinary Shares at an average price of 87.28 pence per Ordinary Share. Additionally, Kieron Harbinson has notified the Company that he has sold a further 175,000 Ordinary Shares in the Company at an average price of 89.76 pence per Ordinary Share. As a consequence, the equity interests of the Exercising Directors following the above transactions are as follows:

Director	Current Ordinary Share holding	Options exercised	Ordinary Shares sold	Resultant Ordinary Share holding	Resultant holding as a % of issued share capital post Admission	Options held post exercise
William Rhodes	nil	300,000	300,000	nil	nil	1,830,406
Jeremy Millard	525,000	166,666	166,666	525,000	0.29%	333,334
Jag Grewal	235,746	210,000	210,000	235,746	0.13%	1,200,000
Kieron Harbinson	717,531	940,000	1,115,000	542,531	0.30%	750,000

Application will be made to the London Stock Exchange for the 1,691,013 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 19 February 2021.

Following Admission, the total number of Ordinary Shares in issue will be 181,758,167 and the total number of voting rights will therefore be 181,758,167. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Contacts: 

Omega Diagnostics Group PLC		Tel: 01259 763 030
Colin King, Chief Executive		www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd		Tel: 020 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited	Tel: 020 7933 8780 or [email protected]
Paul McManus		Mob: 07980 541 893
Lianne Cawthorne		Mob: 07584 391 303

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	William Rhodes
2	Reason for notification
a.	Position/Status	Non-Executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Omega Diagnostics Group Plc
b.	LEI	2138007U9P4BTZTYIR92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 4 pence each ISIN: GB00B1VCP282
b.	Nature of the transaction	Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
15.25p	300,000	Purchase
	87.2797p	300,000	Sale
d.	Aggregated information Aggregated Purchase Volume Aggregated Purchase Price Aggregated Sale Volume Aggregated Sale Price	As above.
e.	Date of the transaction	12 February 2021
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Jeremy Millard
2	Reason for notification
a.	Position/Status	Non-Executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Omega Diagnostics Group Plc
b.	LEI	2138007U9P4BTZTYIR92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 4 pence each ISIN: GB00B1VCP282
b.	Nature of the transaction	Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
10p	166,666	Purchase
	87.2797p	166,666	Sale
d.	Aggregated information Aggregated Purchase Volume Aggregated Purchase Price Aggregated Sale Volume Aggregated Sale Price	As above.
e.	Date of the transaction	12 February 2021
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Jag Grewal
2	Reason for notification
a.	Position/Status	Commercial Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Omega Diagnostics Group Plc
b.	LEI	2138007U9P4BTZTYIR92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 4 pence each ISIN: GB00B1VCP282
b.	Nature of the transaction	Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
13.25p 14.5p	100,000 110,000	Purchase
	87.2797p	210,000	Sale
d.	Aggregated information Aggregated Purchase Volume Aggregated Purchase Price Aggregated Sale Volume Aggregated Sale Price	210,000 13.90p 210,000 87.2797p
e.	Date of the transaction	12 February 2021
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Kieron Harbinson
2	Reason for notification
a.	Position/Status	Chief Finance Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Omega Diagnostics Group Plc
b.	LEI	2138007U9P4BTZTYIR92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 4 pence each ISIN: GB00B1VCP282
b.	Nature of the transaction	Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
14.5p 30.5p	300,000 640,000	Purchase
	87.2797p 89.76p	940,000 175,000	Sale
d.	Aggregated information Aggregated Purchase Volume Aggregated Purchase Price Aggregated Sale Volume Aggregated Sale Price	940,000 25.39p 1,115,000 87.66p
e.	Date of the transaction	12 February 2021
f.	Place of the transaction	London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Jamie Yexley
2	Reason for notification
a.	Position/Status	Operations Director / PDMR
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Omega Diagnostics Group Plc
b.	LEI	2138007U9P4BTZTYIR92
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 4 pence each ISIN: GB00B1VCP282
b.	Nature of the transaction	Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
18.4p	5,869	Purchase
	82.25p	5,869	Sale
d.	Aggregated information Aggregated Purchase Volume Aggregated Purchase Price Aggregated Sale Volume Aggregated Sale Price	As above.
e.	Date of the transaction	12 February 2021
f.	Place of the transaction	London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBBGDDUDBDGBS